KLS-13019 is an orally active GPR55 receptor antagonist and a structural analogue of cannabidiol (CBD). It can prevent and reverse chemotherapy-induced peripheral neuropathy (CIPN) in a dose-dependent manner in rats.
Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > GPR55
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.